Loading...
•
Mar 31, 2020
Beam Therapeutics Q1 2020 Earnings Report
Beam Therapeutics reported its first quarter 2020 financial results and presented additional data at the ASGCT Annual Meeting.
Key Takeaways
Beam Therapeutics reported its Q1 2020 financial results, highlighting a net loss of $31.7 million, or $1.03 per share, and a cash position of $253.4 million. The company also presented promising data from its base editing programs at the ASGCT Annual Meeting, including in vivo proof of concept for alpha-1 antitrypsin deficiency and potential best-in-class approaches for sickle cell disease.
Presented in vivo proof of concept for base editing in alpha-1 antitrypsin deficiency.
Showcased two potentially best-in-class approaches for base editing in sickle cell disease.
Observed more than 90% editing and a more than 65% increase in gamma globin levels in HPFH program.
Cash, cash equivalents and marketable securities were $253.4 million as of March 31, 2020.
Beam Therapeutics
Beam Therapeutics
Forward Guidance
Beam Therapeutics continues to execute its business objectives for 2020, while closely monitoring the impact of the evolving COVID-19 pandemic and advancing critical research and development activities to support an initial wave of Investigational New Drug (IND) applications beginning in 2021.